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Abstract
In vitro studies have well established the neuroprotective action of the noble gas argon. However, only limited data from in
vivo models are available, and particularly whether postexcitotoxic or postischemic argon can provide neuroprotection in
vivo still remains to be demonstrated. Here, we investigated the possible neuroprotective effect of postexcitotoxic-
postischemic argon both ex vivo in acute brain slices subjected to ischemia in the form of oxygen and glucose deprivation
(OGD), and in vivo in rats subjected to an intrastriatal injection of N-methyl-D-aspartate (NMDA) or to the occlusion of
middle-cerebral artery (MCAO). We show that postexcitotoxic-postischemic argon reduces OGD-induced cell injury in brain
slices, and further reduces NMDA-induced brain damage and MCAO-induced cortical brain damage in rats. Contrasting with
its beneficial effect at the cortical level, we show that postischemic argon increases MCAO-induced subcortical brain
damage and provides no improvement of neurologic outcome as compared to control animals. These results extend
previous data on the neuroprotective action of argon. Particularly, taken together with previous in vivo data that have
shown that intraischemic argon has neuroprotective action at both the cortical and subcortical level, our findings on
postischemic argon suggest that this noble gas could be administered during but not after ischemia, i.e. before but not after
reperfusion has occurred, in order to provide cortical neuroprotection and to avoid increasing subcortical brain damage.
Also, the effects of argon are discussed as regards to the oxygen-like chemical, pharmacological, and physical properties of
argon.
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Introduction
Acute brain ischemia is primarily caused by a disruption of
cerebral blood flow through thromboembolism that leads to an
oxygen and glucose deprivation, excessive glutamate release and
subsequent postsynaptic overstimulation of glutamate receptors, a
process known to be critical in ischemia-induced neuronal death
[1–3]. Over the past 10 years, a series of in vitro and in vivo
studies in models of hypoxic/ischemic insults has demonstrated
the neuroprotective potential of some inert gases, among which
xenon has been identified as the most promising agent [4–13].
However, the major obstacle to the widespread clinical use of
xenon is its scarceness and excessive cost of production.
Interestingly argon, which is a cost-efficient and easily available
gas with no narcotic and anesthetic action at normal atmospheric
pressure, has been also shown to provide organoprotection and
neuroprotection against hypoxic-ischemic insults [14–18] (but see
reference [19] for discrepant results). Recent in vivo studies have
further shown that intraischemic argon at 50 vol% (with the
remainder being 50 vol% oxygen) provides both cortical and
subcortical neuroprotection in rats subjected to transient middle
cerebral artery occlusion (MCAO) [18]. However, despite this
latter study, our knowledge on the ability of argon to provide
neuroprotection in acute ischemic stroke still remains limited and
should be augmented to evaluate the actual neuroprotective
potential of this gas. Particularly, whether argon could provide
neuroprotection when given after ischemia still remained
unknown. This latter point is not trivial since previous data have
shown the critical importance of the time at which inert gases
are administered, during or after ischemia [7,20], to obtain
neuroprotection.
Therefore, in the present report, in order to assess thoroughly
the neuroprotective potential of argon and to determine whether
argon could be a cost-efficient alternative to xenon, we studied the
neuroprotective effect of postischemic argon in vitro in brain slices
exposed to ischemia in the form of oxygen and glucose deprivation
(OGD) and in vivo in rats subjected to transient MCAO-induced
ischemia or NMDA-induced excitotoxic insult.
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Effect of argon on OGD-induced cell injury in vitro
First, we investigated the effect of postischemic argon on
neuronal injury induced by OGD in acute brain slices. Cell injury
was assessed by the release of OGD-induced lactate dehydroge-
nase (LDH). Exposure to OGD led to a sustained increase of LDH
release compared to sham slices (P,0.0001; Fig. 1A,B). Argon
given after OGD, i.e. during the postischemic ‘‘reperfusion’’
period, led to significant changes in OGD-induced LDH release
(P,0.0001), so that LDH levels with argon of 37.5 vol% to 75
vol% were lower than those recorded in OGD control slices
exposed to nitrogen (P,0.0120.0001; Fig. 1A). Maximal
neuroprotection occurred with argon at 50 vol%, and increased
with time (Fig. 1B).
Effect of argon on NMDA-induced neuronal death in vivo
Next, because postsynaptic overactivation of NMDA receptors
plays a critical role in ischemic brain damage, we investigated the
concentration-response effects of argon on NMDA-induced
neuronal death when given 1 h after injection. Intrastriatal
injection of NMDA led to significant brain damage compared to
sham rats injected with saline (P,0.001). Argon of 15 vol% to 75
vol% reduced NMDA-induced brain damage (P,0.05), so that
rats treated with argon at 37.5 vol% or 50 vol% had reduced brain
damage compared to control animals treated with medical air
(P,0.02–0.05; Fig. 2).
Effects of argon on MCAO-induced brain damage and
behavioral motor alterations
Next, based on the ex vivo and in vivo findings above that indicate
that maximal neuroprotection by postinsult argon occurs at 50
vol%, we studied the effects of postischemic argon at 50 vol% on
MCAO-induced brain damage and neurologic deficits. When
given 1 h after reperfusion, i.e. 2 h after MCAO induction, argon
reduced cortical volumes of brain damage by ,35% (P,0.02;
Fig. 3A) but increased subcortical brain damage by ,35%
(P,0.02; Fig. 3A) compared to control rats treated with air. At the
behavioral motor level, MCAO rats treated with argon still
exhibited a decreased score of neurologic outcome on day 1
(P,0.0001) and day 2 (P,0.0001) postischemia as compared to
sham rats (Fig. 3B) due to marked deficits in motor coordination
and rearing activity similar to those of control rats treated with
medical air (Fig. 3C; P,0.0001). Also, argon did increase the rats’
body temperature by 1.1uC( P,0.0001), but had no effect on other
physiological parameters (Table 1).
Discussion
The present study shows that argon given after an excitotoxic or
ischemic insult reduces cell injury induced by OGD ex vivo,
subcortical (mainly striatal) neuronal death induced by NMDA
injection, and cortical brain damage induced by MCAO. In
contrast with these beneficial effects, postinsult argon did increase
subcortical brain damage and failed to reduce neurologic deficits
induced by MCAO.
Figure 1. Reduction by argon (Ar) of OGD-induced LDH release. (A) Concentration-response effects of argon (Ar) on OGD-induced LDH
release (n=23–27 per group). Exposure to OGD led to an increase in LDH release. Argon of 37.5 vol% to 75 vol% significantly reduced the increase in
LDH release induced by OGD. (B) Time-course effects of OGD-induced cell injury and argon-induced neuroprotection. Cell injury induced by OGD as
well as neuroprotection by argon increased as a function of time during the 3-h ‘‘reperfusion’’ period. Data are expressed as mean 6 SEM. * P,0.05
vs OGD control slices;
+ P,0.05 vs sham slices.
doi:10.1371/journal.pone.0030934.g001
Figure 2. Concentration-response effects of argon (Ar) on
NMDA-induced neuronal death (n=7–11 per group). Injection of
NMDA led to significant neuronal death. Sham rats had no brain
damage data not shown). Rats treated with argon at 37.5 vol% and 50
vol% had a significant reduction of neuronal death as compared to
NMDA control animals treated with medical air. Data are expressed as
the median value and 25–75
th percentiles * P,0.05 vs NMDA control
rats treated with medical air.
doi:10.1371/journal.pone.0030934.g002
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least partly its neuroprotective action. As reported by Semenov,
the Nobel Prize Laureate of chemistry in 1956 with Sir Cyril
Norman Hinshelwood for their work about branched chain
reactions, argon that is incapable of chemical reactions behaves
however as a sort of catalyst for some of them by producing a kind
of oxygen synergy [21]. In that way, physiological studies have
clearly demonstrated that argon at 50 vol% allowed rats exposed
to hypoxic conditions incompatible with life to adapt and maintain
their oxygen demand [22] Also, argon of 25 to 80 vol% increased
survival in rats exposed to normocapnic or hypercapnic hypoxia,
and conversely potentiated oxygen-induced convulsions [22]. In
addition, in rats exposed to non-lethal hypoxia (7 vol% oxygen for
1 hour), argon restored by ,35% the mitochondrial respiratory
enzyme activity [22], whose impairment following excitotoxic
insults triggers neuronal death [23,24]. Such a kind of argon-
oxygen synergism could explain the neuroprotective effects of
argon against hypoxia [14] and ischemia as reported in the present
and previous studies [15,17,18]. Also, since previous data have
shown redox modulation of the NMDA receptor with reduction
inducing a potentiation and oxidation an inhibition of the NMDA
receptor activity and glutamate-induced neuronal death [25,26],
the synergistic effect of argon on oxygen could explain its ability at
reducing NMDA-induced neuronal death (a normoxic excitotoxic
model). Indeed, in line with these data and the ability of argon at
reducing NMDA-induced neuronal death, intrainsult oxygen has
been shown to have antiexcitotoxic effects and to reduce NMDA-
induced neuronal death and intraneuronal calcium influx [27], a
critical event known to play a major role in excitotoxic and
ischemic brain damage [1–3].
In contrast with its beneficial effect at the cortical level, we
found that postischemic argon did increase MCAO-induced
subcortical brain damage and further failed to reduce MCAO-
induced neurologic deficits. This latter effect is in line with
previous data that have demonstrated that neuroprotection
requires preserving 80–90% of both the cortex and the subcortical
areas to provide significant neurologic recovery and further
predicted that 30% of subcortical brain damage might be sufficient
to suppress any voluntary motor behavior [28]. Physiologically,
the striatum that is the main part of the subcortical brain areas
that suffer MCAO-induced brain damage is well recognized to be
difficult to protect due to its lack of collateral vasculature and
dramatic reduction in cerebral blood flow and oxygen supply as
compared to the cortex. In these conditions, the occurrence of
argon-induced oxygen synergy would not be possible as it occurs
in brain slices exposed to OGD, where oxygen diffusion exists at
the air-saline solution interface, in the cortex of rats subjected to
MCAO-induced ischemia, where residual oxygen exists due to
collateral vasculature, and in the striatum of rats subjected to
NMDA injection that is a normoxic model of excitotoxic insult.
Also, in contrast with the hypothermia-mediated neuroprotective
effects of helium shown to result from the specific heat of helium
that is higher than that of air [29], we found that argon as it could
be expected from its specific heat that is half that of air produces
mild hyperthermia, a condition well known to worsen ischemic
Figure 3. Effects of argon (Ar) at 50 vol% on MCAO-induced brain damage and behavioral motor deficits (n=14 per group). (A)
Control rats subjected to MCAO (treated with medical air) exhibited significant cortical and subcortical brain damage. Sham rats had no brain damage
(data not shown). Argon at 50 vol% produces cortical neuroprotection, but did increase subcortical brain damage. (B) MCAO-induced global score of
neurologic outcome. Control rats (line with black boxes), but not sham rats (line with white boxes), exhibited neurological deficits. Rats treated with
argon at 50 vol% (line with gray boxes) showed no improvement of neurologic deficits as compared to control rats treated with medical air. (C)
Scores of motor coordination and rearing activity in sham rats, control animals treated with medical air, and rats treated with argon at 50 vol%. Data
are expressed as mean 6 SEM. * P,0.05 vs MCAO control rats treated with medical air;
+ P,0.05 vs sham rats.
doi:10.1371/journal.pone.0030934.g003
Table 1. Physiological parameters in control rats treated with
medical air and rats treated with argon at 50 vol% before and
after MCAO-induced ischemia.
PaO2 PaCO2 SaO2 Arterial pH Temp.
Medical Air
Before 94.365.1 32.564.8 97.260.6 7.4160.04 37.360.3
After 95.0622.2 34.068.0 96.760.2 7.4060.05 37.560.2
Argon 50 vol%
Before 92.6613.3 32.062.2 97.260.6 7.4260.01 37.260.4
After 91.563.9 32.561.7 97.260.3 7.4260.01 38.560.6*
Values are expressed as mean 6 SD. PaO2: arterial oxygen partial pressure in
mmHg; PaCO2: arterial carbon dioxide partial pressure in mmHg; SaO2: arterial
hemoglobin saturation of oxygen in %; Temp.: rats’ body temperature in uC.
Administration of argon at 50 vol% significantly decreases the rats’ body
temperature by 1.1uC.
*P,0.0001.
doi:10.1371/journal.pone.0030934.t001
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dramatically suffering subcortical brain areas as compared to the
cortex. This latter possibility is in line with previous investigations
that have shown that, in contrast with the cortex, neuroprotection
of the striatum is tenuous and can be no longer obtained when
time-to-treatment with xenon increases from 1 to 2 h after
induction of ischemia or when blood/gas solubility (that is
inversely proportional to diffusion) increases from 0.12 to 0.46 as
a function of whether xenon or nitrous oxide is used to provide
neuroprotection [30]. Finally, if one consider that argon would act
by modulating membrane proteins [31] and particularly by
potentiating the c-amino-butyric acid type A (GABAA) receptor-
mediated inhibitory neurotransmission [32], the present finding
that postischemic argon provides no improvement of neurologic
outcome while reducing cortical but not subcortical brain damage
is in good agreement with a recent clinical study that has reported
– in contrast with histological studies in animal models [33,34] –
that administration after reperfusion of GABAA agonists, but not
of anti-cholinergic drugs, disrupts the neuronal plasticity that
supports functional recovery in stroke patients and thereby
reinduces clinical deficits after stroke [35]. In line with this latter
study, it has to be noted that xenon that provides dramatic
postischemic neuroprotection possesses efficient antagonistic
properties at the cholinergic neurotransmission [36].
It is noteworthy that the lack of neuroprotective effect of argon
on ischemia-induced subcortical brain damage reported herein
opposes recent data that have demonstrated argon-induced
subcortical (and cortical) neuroprotection [18]. Rather than an
actual discrepancy (different results obtained from similar
experimental conditions), it is likely with little doubt that this
can be attributed to major differences in the protocol used.
Particularly, administration of argon during ischemia [18] or after
ischemia (in the present report) could have played a major role,
since previous studies have shown the critical importance of the
time inert gases are given, during or after ischemia, to obtain
neuroprotection [7,20]. Also, in contrast with the work by Ryang
and colleagues [18] where intraischemic argon was given for 1 h
through a face mask in anesthetized rats, in the present study
postischemic argon was given for 3 h in freely-moving animals not
controlled for temperature in an anesthesia box, an environmental
condition shown to allow the effect of inert gases on body
temperature to occur much more rapidly than using face mask
[37]. Finally, whether neuroprotection by intraischemic argon
together with 50 vol% oxygen (vs 25 vol% oxygen+25 vol%
nitrogen in the present study) can be fully attributed to argon
remains actually and highly questionable since intraischemic
oxygen has been shown to reduce ischemic brain damage both
through anti-excitotoxic and thrombolytic processes (David et al.,
unpublished data).
The present study has possible weaknesses that must be
discussed. First, although there is no real alternative to use an
anesthetic such as isoflurane to induce transient brain ischemia,
the impact of isoflurane administration in combination with 100
vol% oxygen on the findings of this study must be examined.
Indeed, since isoflurane is known as a neuroprotectant precondi-
tioning agent in the adult but not in the newborn rat [38–43], it is
possible that residual isoflurane could have contributed at least
partly to provide neuroprotection against MCAO-induced cortical
brain damage. Conversely, it is possible that residual isoflurane
could have contributed to increase MCAO-induced subcortical
brain damage by producing apoptosis, an adverse effect of
isoflurane yet demonstrated when given in combination with
nitrous oxide but not alone [38,41]. Likewise, since oxygen has
been shown either to reduce or to increase excitotoxic and/or
ischemic brain damage [27,44,45], it is possible that the use of 100
vol% oxygen to induce isoflurane anesthesia could have
contributed also to reduce cortical brain damage and/or to
increase subcortical brain damage. However, these possibilities are
unlikely to be true since in the present study (i) the total duration of
surgery was no more than 25 minutes, thereby allowing rapid
isoflurane and oxygen desaturation from the rat’s body and brain
and thereby the virtual absence of residual isoflurane and oxygen
during the period of treatment with argon [46]; (ii) isoflurane was
never given in combination with argon. Support for this are
previous data with the same protocol that have shown that xenon,
in contrast with what found in the present study with argon,
provides neuroprotection both at the cortical and subcortical levels
[6]. Second, in this study, cerebral blood flow was not measured
throughout MCAO since we wanted to shorten anesthesia to limit
isoflurane effects. However, this should not have biased our results
since postischemic argon obviously induces neuroprotective and
adverse effects at the cortical and subcortical level respectively.
Indeed, it is unlikely that such a dichotomic response could be
attributed to a technical problem of occlusion/reperfusion, which
if such should have biased data in the same way at the cortical and
subcortical level.
In conclusion, our results do not support that postischemic
argon could be an efficient alternative to xenon, shown to provide
dramatic postischemic neuroprotection. However, given its
antiexcitotoxic effect, it is possible that argon could be useful for
treating other brain insults, such as brain trauma.
Materials and Methods
Animals
All animal-useprocedureswere examinedbyalocalethiccommittee
(Cyceron, Caen, France) in accordance with the European Commu-
nities Council Directive for the use of animals in biomedical ex-
perimentation (Declaration of Helsinki), and approved with permit
number 14–27. Adult male Sprague-Dawley rats (Janvier, Le Genest
Saint-Isle, France) weighing 250 to 280 g were housed with food and
water ad libitum by group of six (before surgery) or individually (after
surgery) at a room temperature of 2160.5uCw i t hl i g h t so nf r o m8 : 0 0
pm to 8:00 am.
Ex vivo OGD studies
OGD studies were performed as detailed previously [6].
Coronal brain slices of 400 mM thickness including the striatum
were cut and allowed to recover at room temperature for 45 min
in freshly prepared oxygenated artificial cerebrospinal fluid
(aCSF). Cell injury was assessed by performing LDH activity
assay. Brain slices were incubated individually at 3660.5uCi n
oxygenated aCSF. After stabilisation of LDH release, the
incubation aCSF was renewed and the slices were incubated for
1 h to allow recording basal LDH levels. Sham slices were
incubated for an additional 20-min period in the same conditions.
Brain slices subjected to OGD were incubated in a glucose-free
solution continuously saturated with 100 vol% nitrogen. Then, to
mimic reperfusion and treatment, the medium was replaced in all
groups with aCSF continuously saturated with: (i) medical air; or
(ii) argon of 25 vol% to 75 vol% (with the remainder being oxygen
at 25 vol% completed with nitrogen when necessary). During the
3-h ‘‘reperfusion’’ period, aCSF was renewed every 1 h to obtain
samples and to assess the kinetics of LDH release as a percentage
change from LDH control value before OGD. The number of
animals and slices per group was N=4 and n=23–27,
respectively.
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NMDA studies were performed aas detailed previously [6].
Briefly, rats were anesthetised with 1.5% halothane in oxygen
alone, mounted on a stereotaxic apparatus, allowed breathing
spontaneously, and maintained normothermic at 3760.5uC. Rats
were given 70 nmol NMDA in 1 mL PBS (pH 7.4) into the right
striatum. Total duration of surgery was no more than 10 min,
thereby allowing rapid halothane and oxygen desaturation from
the rat’s body, and the virtual absence of residual halothane and
oxygen during post-NMDA treatment with medical air or argon
[46]. The animals waked up in their home cage after about
10 min, with free access to food and water. Sixty minutes after
injection of NMDA, the rats were treated as described below with
either (i) medical air (controls); or (ii) argon of 25 vol% to 75 vol%
(with the remainder being 25 vol% oxygen completed with
nitrogen when necessary). The number of rats per group was as
follows: 75 vol% argon, n=7; 50 vol% argon, n=8; 37.5 vol%
argon, n=8; 25 vol% argon, n=8; 15 vol% argon, n=8; NMDA
control group, n=11. Sham rats were given an intrastriatal saline
solution and medical air.
In vivo MCAO studies
MCAO studies were performed as described in details
previously [6]. Briefly, rats were subjected to transient cerebral
ischemia for 60 min by the intraluminal MCAO method using a
nylon thread. Rats were anesthetised with 1.5% isoflurane in
oxygen alone, allowed breathing spontaneously, and maintained
normothermic at 37.5uC60.5uC. Total duration of surgery was no
more than 25 min, thereby allowing rapid isoflurane and oxygen
desaturation from the rat’s body, and little residual isoflurane and
oxygen during the MCAO period [46]. After surgery, rats were
allowed moving freely in their home wages with free access to food
and water. Sixty minutes later, the nylon was removed under a
short isoflurane anesthesia of less than 10 min duration, thereby
allowing rapid isoflurane and oxygen desaturation from the rat’s
body, and the virtual absence of residual isoflurane and oxygen
during the rats’ reperfusion and 3-h post-MCAO treatment with
either medical air (MCAO controls, n=14) or argon at 50 vol%
(n=14) [46]. Treatment with medical air or argon at 50 vol% was
performed according to a blinded procedure in a closed chamber
at a flow rate of 1 chamber volume per minute, a condition that
allowed maintaining carbon dioxide less than 0.03%. No analgesic
treatment was given during recovery. Physiological parameters
were recorded immediately before and immediately after treat-
ment with medical air or argon at 50 vol%. Sham-treated rats
(n=6) were subjected to the same surgical protocol than controls
and argon-treated rats, but not to ischemia, and exposed to
medical air for 3 h.
The rats’ neurologic outcome was assessed by recording the
animals’ motor coordination and rearing activity as detailed
previously [6]. Motor coordination was quantified in individual
non-motorized activity wheels equipped with 1/8 rotation sensors;
rearing activity was quantified in individual activity cages equipped
with infrared beams (Imetronic, Pessac, France). Beam interruptions
and rotation signals were detected and recorded on a computer. Rats
were familiarized with the activity cages and wheels. Then, on day 2
before MCAO (248 h), and on day 1 (24 h) and day 2 (48 h) after
MCAO, the rats were placed again and recorded for 15 min in the
activity cages and the activity wheels. Post-MCAO scores of motor
coordination and rearing activity were expressed as a percentage of
pre-MCAO scores on day 2 before MCAO using each rat as its own
control, and averaged to obtain a global score of neurologic outcome
expressed as a percentage of that recorded in sham rats.
Histologic analysis
Fifty hours after MCAO or NMDA injection, coronal brain
sections(20 mm)were cryostat-cut, stained with thionin, digitized on a
computer and analysed using an image analyzer (ImageJH software,
Scion corp., USA). The infarction volume was calculated by
integration over the whole brain of the infarcted surfaces delineated
by the pallor of staining compared to the surrounding healthy tissue,
corrected for tissue oedema when needed (MCAO-induced ischemia)
by calculating and dividing volume by the ipsilateral/contralateral
brain hemispheres ratio, and expressed in mm
3.
Gas treatment
Oxygen, nitrogen and argon of medical grade were bought from
Messer and Air Liquide. Gas mixtures containing 75 vol%
nitrogen and 25 vol% oxygen (medical air), or argon of 15 vol% to
75 vol% (with the remainder being oxygen at 25 vol% completed
with nitrogen when necessary) were obtained using calibrated
flowmeters and gas analysers.
Statistical analysis
Data on OGD-induced LDH release (n.20) are expressed as
the mean 6 the standard error to the mean (SEM) and were
analysed using one-way parametric ANOVA and post-hoc
unpaired Student t-test. Data on MCAO-induced brain damage
(n,20) are expressed as the median value 6 the 25–75
th
percentiles and were analysed using the Kruskall-Wallis nonpara-
metric ANOVA and/or post-hoc Mann-Whitney unpaired U-test.
The number of animals per group for the in vivo studies was
assessed through power analysis through online software (www.
dssresearch.com/toolkit/sscalc/size_a2.asp). Because one objec-
tive of the study was to assess whether or not argon could be a cost-
efficient alternative to xenon, the number of rats was calculated
with the following variables from a previous study from our
laboratory [6] with xenon at 50 vol%: mean 6 standard deviation
(SD) for ischemic brain damage volume in control
group=218660 mm
3; mean 6 SD for ischemic brain damage
volume in xenon-treated group=59628 mm
3; a error level
(confidence level)=0.05; b error level (statistical power)=0.01.
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